Top Page
4DMedical Ltd
(Sydney:4DX)
4DMedical Ltd (4DX) vs. S&P 500 (SPY)
4DMedical Ltd Business Overview & Revenue Model
4DMedical Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.86M | 3.75M | 282.18K | 1.05M | 216.98K | 1.23M | Gross Profit |
| 5.48M | 3.52M | 248.03K | 280.62K | 125.13K | -8.13M | EBIT |
| -27.46M | -27.97M | -31.13M | -36.75M | -18.78M | -15.96M | EBITDA |
| -44.64M | -31.86M | -33.74M | -36.34M | -18.04M | -15.77M | Net Income Common Stockholders |
| -39.54M | -35.98M | -31.46M | -24.59M | -21.42M | -21.98M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.95M | 30.61M | 69.58M | 51.11M | 80.88M | 8.43M | Total Assets |
| 102.01M | 120.02M | 92.92M | 74.31M | 92.64M | 15.82M | Total Debt |
| 4.82M | 5.12M | 5.14M | 6.24M | 1.69M | 16.49M | Net Debt |
| -11.13M | -25.49M | -64.44M | -44.88M | -79.19M | 8.06M | Total Liabilities |
| 42.15M | 49.09M | 21.46M | 14.80M | 9.28M | 27.63M | Stockholders Equity |
| 59.86M | 70.93M | 71.46M | 59.51M | 83.36M | -11.81M |
| Cash Flow | Free Cash Flow | ||||
| -30.37M | -31.17M | -23.38M | -28.35M | -15.25M | -8.81M | Operating Cash Flow |
| -30.28M | -30.87M | -22.65M | -25.27M | -14.52M | -7.65M | Investing Cash Flow |
| -1.52M | -40.04M | -1.61M | -3.50M | -580.45K | -786.45K | Financing Cash Flow |
| -127.96K | 31.94M | 42.73M | -995.47K | 87.55M | 13.78M |
4DMedical Ltd Technical Analysis
4DMedical Ltd Peers Comparison
4DMedical Ltd Corporate Events
4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.
4DMedical Ltd has released its First 20 Investors Report, detailing the top investors holding significant shares in the company. The report reveals that the top 20 investors collectively hold 51.61% of the company’s issued capital, with CITICORP NOMINEES PTY LIMITED leading at 21.15%. This concentration of ownership among a few key investors could impact the company’s strategic decisions and market influence.
4DMedical Ltd has announced the application for quotation of new securities on the ASX, specifically options expiring on February 28, 2026. This move involves issuing listed options to participants of their recent SPP and placement, potentially enhancing the company’s capital structure and market presence.
4DMedical Limited announced that all resolutions proposed at its Extraordinary General Meeting were successfully passed. This outcome supports the company’s strategic initiatives, including the ratification of share issues and the approval of new options, which are expected to strengthen its financial position and operational capabilities. These developments are likely to enhance 4DMedical’s industry positioning and provide further value to its stakeholders.
4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.
4DMedical Ltd has announced the quotation of 131,498 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. These securities were issued as part of an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to incentivize and retain talent within the company.
4DMedical Limited has lodged a supplementary prospectus with the Australian Securities and Investments Commission, amending the terms of its New Options and Piggyback Options offers. The company has streamlined the application process for eligible participants, who will automatically be deemed to have applied for their allocation unless they choose to opt out. This move aims to simplify participation and potentially increase stakeholder engagement in anticipation of future FDA clearance for its CT:VQ technology.
4DMedical Limited has announced a change in the address of its registry office in Sydney, effective from April 14, 2025. This move is part of the company’s ongoing efforts to streamline its operations and maintain compliance with ASX regulations. The change is not expected to impact the company’s operations or its stakeholders significantly, as contact details remain unchanged.
4DMedical Limited has successfully transitioned its pilot program with Integral Diagnostics into a commercial contract, marking a significant expansion of its lung imaging technology across Victoria, Australia. This development will enhance access to 4DMedical’s advanced diagnostic tools for general practitioners, respiratory specialists, and cardiologists, improving patient outcomes through more accurate and timely diagnoses of respiratory conditions. The contract signifies strong demand for 4DMedical’s innovative solutions and reinforces its commitment to revolutionizing lung health, further solidifying its commercial presence in the Australian market.
4DMedical Limited has secured two new contracts to supply its advanced lung imaging technology for clinical trials, one with SMS Biotech for a COPD stem cell therapy trial and another with an unnamed medical device developer. This highlights 4DMedical’s growing role in the respiratory health sector and its strategic partnerships aimed at advancing lung disease treatments. Additionally, 4DMedical’s technology was featured in a US Congressional testimony by Philips, emphasizing its potential to improve veteran healthcare outcomes through enhanced pulmonary diagnostics.
4DMedical Limited has announced an Extraordinary General Meeting scheduled for May 1, 2025, in Melbourne, Australia. The meeting will address several business matters, including the ratification of shares issued under a placement and the approval of new options. This meeting is significant for stakeholders as it involves key decisions impacting the company’s financial strategies and shareholder interests.
4DMedical Limited has announced a strategic review resulting in a cost reduction program expected to save $6.5 million annually. This initiative, alongside a successful $13.9 million capital raise, aims to optimize operational efficiency without impacting revenue growth or key milestones. The company is focusing on expanding its commercial activities, particularly in the US, and advancing its CT:VQ™ technology post-FDA clearance. Changes in company leadership include the appointment of Chris Cox as Interim CFO and Hamish George as Company Secretary. These measures are intended to safeguard the company’s long-term growth and financial stability.
4DMedical Ltd has announced a target market determination related to the issuance of new quoted options and piggyback options, which are tied to the company’s shares. These options are part of a prospectus set to be lodged in March 2025, aimed at institutional and sophisticated investors, eligible shareholders, and sub-underwriters. The options are designed to facilitate the trade of shares upon exercise, with the issuance subject to shareholder approval and ASX quotation requirements. This move is expected to enhance the company’s market positioning by potentially increasing share liquidity and attracting more investors.
4DMedical Ltd has announced a series of options offers, including SPP Options, Placement Options, Sub-Underwriter Options, and Piggyback Options, aimed at providing shareholders and eligible participants with opportunities to acquire new options. These offers are contingent upon obtaining shareholder approval under ASX Listing Rule 7.1. The initiative is part of the company’s strategic financial maneuvers to enhance its market position and provide value to its stakeholders.
4DMedical Limited has successfully completed an oversubscribed Securities Purchase Plan (SPP), raising $8.4 million, which, combined with a previous $5.5 million Placement, totals $13.9 million. These funds will support the company’s efforts to commercialize its lung diagnostics portfolio and advance the FDA submission of its CT:VQ™ technology. The capital raised positions 4DMedical to enhance its market presence and continue developing innovative respiratory diagnostic tools, benefiting shareholders and the broader healthcare industry.
4DMedical Ltd announced the cessation of 3,781,171 securities due to the expiry of options or other convertible securities without exercise or conversion as of March 1, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
4DMedical Limited announced a change in the director’s interest, specifically involving Julian Bernard Kingsley Sutton. The announcement detailed the expiry of certain unquoted options held by Sutton, resulting in a decrease in his indirect interest in the company’s securities. This change in director’s interest may affect stakeholder perceptions of the company’s governance and financial strategies.
4DMedical Limited announced a change in the directors’ interests due to the expiry of options on March 1, 2025, involving directors Andreas Fouras and Julian Sutton. Importantly, no securities held by these directors or their related parties have been sold, indicating a stable position in their holdings. This announcement is part of routine disclosures under ASX listing rules and does not imply any immediate impact on the company’s operations or market strategy.
4DMedical Ltd, a company involved in medical technology, has experienced a change in the interests of a substantial holder, Helen Fouras. The change is primarily due to the dilution of shares resulting from the issuance of new ordinary shares. This adjustment has led to a decrease in Helen Fouras’ voting power from 16.81% to 15.38%. The changes in shareholding reflect strategic financial maneuvers within the company, possibly affecting its market positioning and stakeholder interests.
4DMedical Ltd, a company listed as 4DX, has announced a change in the interests of its substantial holder, Andreas Fouras. The voting power of Andreas Fouras has decreased from 16.81% to 15.38% due to the issuance of additional ordinary shares. This change reflects a dilution of Fouras’s stake in the company, which could have implications for his influence over company decisions.
4DMedical Limited announced a change in the interests of substantial holders due to the dilution of shares from recent placements. Despite the decrease in voting power, no shares were sold by Velocimetry Consulting Pty Ltd, Andreas Fouras, or Helen Fouras. This announcement reflects the company’s ongoing strategic adjustments and could influence stakeholder perceptions regarding its market positioning.
4DMedical Limited has successfully raised $5.5 million through the issuance of 12,941,176 new shares to institutional and professional investors at $0.425 per share. This capital raise, conducted under the company’s existing placement capacity, is expected to bolster 4DMedical’s financial position and support its ongoing innovations in respiratory care technology, potentially enhancing its market presence and stakeholder value.
4DMedical Limited has released an investor presentation, emphasizing that it is not a financial product offer or advice. The presentation serves as a general informational update about the company’s operations and is not intended to solicit investment or form the basis of any financial contracts. It highlights the company’s position in the market and provides insights into its ongoing activities, while also noting legal restrictions on the distribution of the presentation outside Australia.
4DMedical Limited announced its half-year results, highlighting a significant increase in operating revenue by 265.3% to $3.8 million, driven by strong support from institutional investors and the launch of a Share Purchase Plan. The company has expanded its operations to 301 sites, delivering over 8,000 scans in the first half of FY2025, and has made substantial progress in commercializing its products, including FDA clearance for its eighth commercial product. The company’s strategic partnerships and recent contract signings are expected to further enhance its revenue stream.
4DMedical Ltd reported a significant increase in revenue from ordinary activities, up 265% to $2,895,000 for the half-year ended December 31, 2024, compared to the same period in 2023. Despite the revenue growth, the company experienced a 23% increase in loss from ordinary activities after tax, amounting to $19,168,000, and a net loss of $12,575,000, down 15% from the previous year. These financial results highlight the company’s ongoing challenges in achieving profitability, despite its strong revenue performance.
4DMedical Ltd announced an update regarding its proposed issue of securities, indicating its intention to apply for quotation of all options detailed in the announcement. However, the company noted that achieving quotation is not guaranteed and is contingent upon meeting specific conditions under ASX Listing Rule 2.5. This move could potentially impact the company’s market presence and stakeholder interests, depending on the outcome of the quotation process.
4DMedical Ltd has announced the application for the quotation of 12,941,176 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective February 28, 2025. This move is part of a previously announced transaction and is expected to bolster the company’s financial position, potentially enhancing its market presence and offering new opportunities for stakeholders.
4DMedical Limited announced an upcoming investor webinar and Q&A session to discuss its 1H FY2025 Half Year Results. The session, led by CEO Dr. Andreas Fouras, aims to update shareholders and investors on the company’s performance and strategic direction. This event underscores 4DMedical’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.
4DMedical Ltd has announced a Share Purchase Plan (SPP) offering eligible shareholders the opportunity to purchase up to $30,000 worth of fully paid ordinary shares without incurring brokerage or transaction costs. The new shares will be issued on March 25, 2025, and will rank equally with existing shares. This initiative is part of 4DMedical’s efforts to strengthen its financial position and support its growth strategy in the medical imaging sector.
4DMedical Ltd has announced a Share Purchase Plan (SPP) allowing eligible shareholders to purchase up to $30,000 worth of new fully paid ordinary shares. This initiative, compliant with ASIC regulations, aims to strengthen the company’s financial position and potentially enhance its market presence, offering stakeholders a chance to increase their investment in the company’s future growth.
4DMedical Limited has received regulatory approval for its CT Lung Ventilation Analysis Software (CT LVAS™) in Canada, enhancing its portfolio of respiratory imaging products in the region. This approval allows 4DMedical to expand its presence in the Canadian healthcare market, which is significantly larger than Australia’s, and positions the company for future growth and potential approval of its CT:VQ™ imaging technology. The approval is expected to improve the diagnosis and monitoring of lung diseases, benefiting patients and healthcare providers by offering valuable insights into lung function without additional imaging or contrast agents.
4DMedical Ltd has announced a proposed issuance of securities, with plans to issue both listed and unlisted options, as well as ordinary fully paid shares. This move is part of a securities purchase plan and additional placements, potentially impacting the company’s capital structure and market positioning by increasing available shares and options. The proposed securities issuance may enhance the company’s financial flexibility and support its growth initiatives, benefiting stakeholders by potentially increasing liquidity and expanding investment opportunities.
4DMedical Limited has announced an investor webinar hosted by its CEO, Dr. Andreas Fouras, to discuss the recent capital raise through a Placement and Share Purchase Plan. This initiative is expected to support the company’s growth and further its mission in redefining respiratory healthcare. Stakeholders are invited to participate in this event, which indicates 4DMedical’s proactive engagement with its investor community and commitment to transparency.
4DMedical Limited has announced a capital raise through the placement of new ordinary shares and a securities purchase plan targeting sophisticated and professional investors. This move is expected to bolster the company’s financial position and support its growth initiatives in the respiratory imaging sector, potentially enhancing its market presence and delivering value to its stakeholders.
4DMedical Limited announced the completion of a A$5.5 million share placement to institutional investors and the launch of a A$7 million underwritten Share Purchase Plan (SPP) for eligible shareholders in Australia and New Zealand. The funds raised will support the company’s commercialization efforts and general working capital. This financial initiative reflects the company’s ongoing commitment to expanding its market presence and enhancing its product offerings, which has resulted in strong growth in site numbers, scan volume, and revenue per scan.